Serum Concentrations of Osteogenesis/Osteolysis-Related Factors and Micro-RNA Expression in ST-Elevation Myocardial Infarction

Table 6

Comparison of osteogenesis/osteolysis factors measured at the baseline between patients with and without ≥5% improvement of LVEF.

Factor (unit)	Patients without at least ≥5% improvement of LVEF (n = 15)	Patients with at least ≥5% improvement of LVEF (n = 10)	value
DKK-1 (pg/ml)	480 (413–704)	510 (396–555)	0.92
TNF-α (pg/ml)	0.91 (0.67–1.22)	1.11 (0.87–1.16)	0.94
OPG (pg/ml)	155 (125–177)	154 (127–209)	0.41
OCN (ng/ml)	5.39 (3.91–6.64)	5.29 (1.34–6.76)	0.82
OPN (ng/ml)	16.12 (14.52–22.57)	19.23 (8.49–22.01)	0.79
NT-proANP (ng/ml)	5.52 (5.02–7.62)	5.82 (3.43–10.71)	0.83
PCSK9 (ng/ml)	60.67 (47.01–83.02)	87.64 (62.76–96.18)	0.07
TSP-2 (ng/ml)	24.93 (20.53–41.19)	26.54 (17.31–32.92)	0.79
TRAIL (pg/ml)	64.4 (61.0–76.7)	61.8 (61.0–62.7)	0.68

DKK-1, Dickkopf-related protein 1; LVEF, left ventricle ejection fraction; NT-proANP, N-terminal atrial natriuretic peptide; OPG, osteoprotegerin; OCN, osteocalcin; OPN, osteopontin; PCSK9, proprotein convertase subtilisin/kexin type 9; TNF-α, tumor necrosis factor alpha; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TSP-2, thrombospondin-2.